{
  "meta": {
    "title": "Heart_Failure_Part_1",
    "url": "https://brainandscalpel.vercel.app/heart-failure-part-1-dee8afdb.html",
    "scrapedAt": "2025-11-30T11:13:02.191Z"
  },
  "questions": [
    {
      "id": 1,
      "choices": [
        {
          "id": 1,
          "text": "<p><span style=\"font-size:12.0pt;\">Amiloride 5 mg OD</span></p>"
        },
        {
          "id": 2,
          "text": "<p><span style=\"font-size:12.0pt;\">Bumetanide 2 mg BD</span></p>"
        },
        {
          "id": 3,
          "text": "<p><span style=\"font-size:12.0pt;\">Metolazone 5 mg OD</span></p>"
        },
        {
          "id": 4,
          "text": "<p><span style=\"font-size:12.0pt;\">Spironolactone 25 mg OD</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 63-year-old man with known chronic heart failure is admitted with dyspnea at rest. On examination, he has pitting edema to his knees, elevated jugular venous pressure, and basal crepitations. He is in sinus rhythm at 80 bpm and has a blood pressure of 100/60 mmHg. His current medications include bisoprolol 10 mg once daily, frusemide 80 mg once daily, and ramipril 2.5 mg twice daily. On admission, he is started on IV frusemide 80 mg twice daily and his ramipril is increased to 5 mg twice daily. When reviewed the following day, what additional drug would be most appropriate to add?</span></p>",
      "unique_key": "DT1192970",
      "question_audio": null,
      "question_video": null,
      "map_id": 1192970,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p>This patient presents with <strong>decompensated chronic heart failure (CHF)</strong>, NYHA class IV (dyspnea at rest), with signs of <strong>volume overload</strong> (leg edema, raised JVP, crepitations).</p>\r\n<p>While increasing diuretics (IV furosemide) helps reduce volume status, this must be accompanied by drugs that target the <strong>pathophysiology and progression of heart failure</strong>, especially <strong>neurohormonal activation</strong> and <strong>ventricular remodeling</strong>.</p>\r\n<p><strong>Spironolactone:</strong></p>\r\n<ul>\r\n<li><strong>Mechanism:</strong> Aldosterone antagonist (mineralocorticoid receptor blocker)</li>\r\n<li><strong>Benefits in CHF:</strong>\r\n<ul>\r\n<li>Reduces sodium and water retention</li>\r\n<li>Limits myocardial fibrosis and adverse remodeling</li>\r\n<li>Improves <strong>symptoms</strong>, <strong>functional class</strong>, and <strong>reduces hospitalizations</strong></li>\r\n</ul>\r\n</li>\r\n<li><strong>Dose:</strong> Typically started at <strong>25 mg OD</strong>, with monitoring of K+ and renal function</li>\r\n<li><strong>Common side effects:</strong> Hyperkalemia, gynecomastia, renal impairment</li>\r\n</ul>\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Amiloride 5 mg OD (Option A):</strong></p>\r\n<ul>\r\n<li><strong>Potassium-sparing diuretic</strong>, weak natriuretic effect.</li>\r\n<li>Not proven to reduce mortality in CHF.</li>\r\n<li>Typically reserved for <strong>hypokalemia prevention</strong>, not for symptom control or prognostic benefit.</li>\r\n</ul>\r\n<p><strong>Bumetanide 2 mg BD (Option B):</strong></p>\r\n<ul>\r\n<li>Another loop diuretic (like furosemide)</li>\r\n<li>May be used as a substitute if poor diuretic response, but not needed here (already receiving high-dose IV furosemide).</li>\r\n<li><strong>Does not address neurohormonal remodeling</strong> or improve survival.</li>\r\n</ul>\r\n<p><strong>Metolazone 5 mg OD (Option C):</strong></p>\r\n<ul>\r\n<li>Thiazide-like diuretic, <strong>used for synergistic diuresis</strong> with loop diuretics in <strong>refractory fluid overload</strong>.</li>\r\n<li>Useful in diuretic resistance, but <strong>no mortality benefit</strong>.</li>\r\n<li>Risk of <strong>profound hypovolemia, electrolyte disturbances</strong>.</li>\r\n</ul>",
      "correct_choice_id": 4,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 2,
      "choices": [
        {
          "id": 11,
          "text": "<p><span style=\"font-size:12.0pt;\">Hyperkalaemia</span></p>"
        },
        {
          "id": 12,
          "text": "<p><span style=\"font-size:12.0pt;\">Hypercalcemia</span></p>"
        },
        {
          "id": 13,
          "text": "<p><span style=\"font-size:12.0pt;\">Hypermagnesaemia</span></p>"
        },
        {
          "id": 14,
          "text": "<p><span style=\"font-size:12.0pt;\">Hyperuricemia</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 79-year-old man with chronic congestive heart failure is readmitted with worsening symptoms. His furosemide dosage is increased to 200 mg/day for symptom relief. He is also on bendrofluazide, ramipril, and bisoprolol. Which of the following adverse effects is most likely to occur following this dose increase?</span></p>",
      "unique_key": "DT1192974",
      "question_audio": null,
      "question_video": null,
      "map_id": 1192974,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p><strong>Furosemide</strong> is a <strong>loop diuretic</strong> that acts on the <strong>Na+-K+-2Cl- cotransporter in the thick ascending limb of the loop of Henle</strong>, resulting in:</p>\r\n<ul>\r\n<li>Potent <strong>natriuresis</strong> and <strong>diuresis</strong></li>\r\n<li>Loss of <strong>sodium</strong>, <strong>potassium</strong>, <strong>calcium</strong>, <strong>magnesium</strong>, and <strong>water</strong></li>\r\n</ul>\r\n<p>Loop diuretics like furosemide reduce renal perfusion and enhance <strong>proximal tubular reabsorption of uric acid (hyperuricemia)</strong>, thereby increasing serum urate levels. This can precipitate <strong>gout</strong>, especially in elderly or predisposed patients.</p>\r\n<p><strong>Adverse effects of Furosemide therapy:</strong></p>\r\n<br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20250922ce3d567d-baa7-4d5e-93c2-b57ac1d57d10.png\">",
      "correct_choice_id": 14,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 3,
      "choices": [
        {
          "id": 21,
          "text": "<p><span style=\"font-size:12.0pt;\">Doxorubicin</span></p>"
        },
        {
          "id": 22,
          "text": "<p><span style=\"font-size:12.0pt;\">Paclitaxel</span></p>"
        },
        {
          "id": 23,
          "text": "<p><span style=\"font-size:12.0pt;\">Cisplatin</span></p>"
        },
        {
          "id": 24,
          "text": "<p><span style=\"font-size:12.0pt;\">Bleomycin</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 52-year-old woman with a history of metastatic breast cancer treated with chemotherapy 6 months ago presents with shortness of breath on exertion. Her blood pressure is 125/78 mmHg, pulse 94/min, and the apex beat is displaced to the anterior axillary line. Chest X-ray shows cardiomegaly and increased shadowing at both lung bases consistent with mild pulmonary edema. Which chemotherapeutic agent is most likely responsible for her symptoms?</span></p>",
      "unique_key": "DT1192980",
      "question_audio": null,
      "question_video": null,
      "map_id": 1192980,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p>The displaced apex beat, cardiomegaly, and pulmonary edema point to dilated cardiomyopathy with left ventricular dysfunction, most likely due to <strong>chemotherapy-induced cardiotoxicity</strong>.</p>\n<ul>\n<li><strong>Doxorubicin (Anthracycline)</strong> leads to <strong>dose-dependent, irreversible cardiomyopathy</strong>.</li>\n<li>It causes oxidative damage and myocyte necrosis, resulting in <strong>reduced ejection fraction</strong> and <strong>congestive heart failure</strong>.</li>\n<li>Risk increases with cumulative doses<strong> &gt;450-550 mg/m2</strong> and in older patients or those with pre-existing cardiac disease.</li>\n</ul>\n<p><strong>Chemotherapy Drugs Causing Dilated Cardiomyopathy:</strong></p>\n<ul>\n<li>Doxorubicin (Adriamycin)</li>\n<li>Trastuzumab (Herceptin)</li>\n<li>Cyclophosphamide</li>\n<li>Zidovudine</li>\n<li>Tacrolimus (rare)</li>\n</ul>\n<p><strong>Drugs Worsening Heart Failure via Fluid Retention:</strong></p>\n<ul>\n<li>NSAIDs</li>\n<li>Thiazolidinediones (pioglitazone)</li>\n<li>Glucocorticoids</li>\n</ul>\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Paclitaxel (Option B): </strong>Associated mainly with <strong>peripheral neuropathy</strong>, <strong>myelosuppression</strong>, and <strong>hypersensitivity reactions</strong>, not cardiomyopathy.</p>\n<p><strong>Cisplatin (Option C): </strong>Known for <strong>nephrotoxicity</strong>, <strong>ototoxicity</strong>, and <strong>peripheral neuropathy</strong>, but not typically cardiotoxic.</p>\n<p><strong>Bleomycin (Option D): </strong>Most known for <strong>interstitial pulmonary fibrosis</strong> and <strong>flagellate dermatitis</strong>, not heart failure.</p>",
      "correct_choice_id": 21,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 4,
      "choices": [
        {
          "id": 31,
          "text": "<p><span style=\"font-size:12.0pt;\">Congestive cardiac failure</span></p>"
        },
        {
          "id": 32,
          "text": "<p><span style=\"font-size:12.0pt;\">Left bundle-branch block</span></p>"
        },
        {
          "id": 33,
          "text": "<p><span style=\"font-size:12.0pt;\">Moderate ventricular septal defect</span></p>"
        },
        {
          "id": 34,
          "text": "<p><span style=\"font-size:12.0pt;\">Right bundle-branch block and heart failure</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following conditions is most likely to produce a wide, relatively fixed split of the second heart sound (S2)?</span></p>",
      "unique_key": "DT1192982",
      "question_audio": null,
      "question_video": null,
      "map_id": 1192982,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation of Answer:</strong></p>\n<p>A wide, fixed split of the second heart sound (S2) refers to a <strong>persistent delay in pulmonary valve closure (P2)</strong> that <strong>does not vary with respiration</strong>, indicating <strong>prolonged right ventricular systole</strong> and <strong>limited respiratory volume variation</strong>.</p>\n<ul>\n<li><strong>Right bundle branch block (RBBB)</strong> delays <strong>right ventricular depolarization</strong>, which in turn <strong>delays pulmonary valve closure</strong>, leading to a <strong>wide splitting</strong> of S2.</li>\n<li><strong>Heart failure</strong>, especially with pulmonary congestion, causes <strong>shallow respiration</strong>, resulting in <strong>minimal respiratory variation</strong> of venous return. This leads to a <strong>relatively fixed split</strong> since the normal inspiratory increase in RV preload (and thus delayed P2) is blunted.</li>\n<li>Together, <strong>RBBB widens</strong> the split and <strong>heart failure fixes</strong> it by limiting respiratory variation.</li>\n</ul>\n<p>This combination <strong>mimics the classical fixed splitting seen in atrial septal defect</strong>, though the mechanism differs.</p>\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Congestive cardiac failure (Option A):</strong> Heart failure alone does not necessarily lead to a wide or fixed split unless accompanied by conduction delays like RBBB. It may reduce respiratory variability in venous return, but without conduction delay, fixed splitting is unlikely.</p>\n<p><strong>Left bundle-branch block (Option B):</strong> LBBB delays aortic valve closure (A2), possibly narrowing or reversing the A2-P2 sequence (i.e., paradoxical splitting). It does not cause a <strong>wide</strong> or <strong>fixed</strong> split.</p>\n<p><strong>Moderate ventricular septal defect (VSD) (Option C):</strong> A moderate VSD may increase pulmonary blood flow, causing <strong>delayed P2</strong> and possibly a <strong>wide split</strong>, but it is <strong>not fixed</strong>. Respiratory variability in preload persists in VSD unless heart failure is severe.</p>\n<p><strong>Key Takeaway:</strong></p>\n<p>Causes of paradoxical splitting of S2 (P2 before A2):</p>\n<ul>\n<li>Severe aortic stenosis</li>\n<li>Left bundle branch block (may also cause narrowly split S2)</li>\n</ul>",
      "correct_choice_id": 34,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 5,
      "choices": [
        {
          "id": 41,
          "text": "<p><span style=\"font-size:12.0pt;\">Increase diuretics and maintain the current dose of &beta;-blocker</span></p>"
        },
        {
          "id": 42,
          "text": "<p><span style=\"font-size:12.0pt;\">Increase diuretics and reduce the &beta;-blocker dose</span></p>"
        },
        {
          "id": 43,
          "text": "<p><span style=\"font-size:12.0pt;\">Increase diuretics and increase the &beta;-blocker dose</span></p>"
        },
        {
          "id": 44,
          "text": "<p><span style=\"font-size:12.0pt;\">Increase diuretics, stop &beta;-blockers and later increase the &beta;-blocker dose when her lungs are dry</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 52-year-old woman with known heart failure on ramipril, furosemide, and bisoprolol presents to the emergency department with acute pulmonary oedema. Her heart rate is 120 bpm, and her blood pressure is 100/65 mmHg. She is given oxygen and diamorphine. Which of the following is the most appropriate next step in her further management?</span></p>",
      "unique_key": "DT1192986",
      "question_audio": null,
      "question_video": null,
      "map_id": 1192986,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p>This patient has <strong>acute decompensated heart failure</strong> (ADHF) with <strong>pulmonary oedema</strong>. The immediate management priorities are to <strong>relieve congestion</strong>, optimize <strong>oxygenation</strong>, and ensure <strong>hemodynamic stability</strong>.</p>\n<ul>\n<li>She is already on <strong>bisoprolol</strong>, a &beta;-blocker, which is part of guideline-directed medical therapy for chronic heart failure with reduced ejection fraction (HFrEF).</li>\n<li>In the setting of <strong>acute decompensation</strong>, <strong>&beta;-blockers should</strong> <strong>not be initiated</strong> or <strong>up-titrated</strong>. However, if the patient is already on a &beta;-blocker, the <strong>current dose </strong>should generally b<strong>e continued</strong> unless there is <strong>severe hypotension, bradycardia, or cardiogenic shock</strong>, none of which is evident here. <strong>(Options B &amp; C ruled out)</strong></li>\n<li><strong>Increasing diuretics</strong> (e.g., intravenous furosemide) is the appropriate step to <strong>offload fluid</strong>, relieve pulmonary congestion, and reduce preload.</li>\n</ul>\n<p><strong>Beta-blockers, when abruptly stopped</strong>, can lead to <strong>rebound sympathetic overactivation</strong>, worsening heart failure further. Maintaining the current dose helps stabilize neurohormonal mechanisms unless contraindications are present. <strong>(Option D ruled out)</strong></p>",
      "correct_choice_id": 41,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 6,
      "choices": [
        {
          "id": 51,
          "text": "<p><span style=\"font-size:12.0pt;\">Digoxin</span></p>"
        },
        {
          "id": 52,
          "text": "<p><span style=\"font-size:12.0pt;\">Furosemide</span></p>"
        },
        {
          "id": 53,
          "text": "<p><span style=\"font-size:12.0pt;\">Angiotensin receptor blocker</span></p>"
        },
        {
          "id": 54,
          "text": "<p><span style=\"font-size:12.0pt;\">Empagliflozin</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 52-year-old male with NYHA class III chronic heart failure is found to have a normal ejection fraction (54%) on echocardiography. Which of the following drugs has been found to be useful in the management of this condition?</span></p>",
      "unique_key": "DT1192990",
      "question_audio": null,
      "question_video": null,
      "map_id": 1192990,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p>This patient has <strong>heart failure with preserved ejection fraction (HFpEF)</strong>, defined as clinical features of heart failure with a left ventricular ejection fraction <strong>(LVEF) &ge;50%</strong>.</p>\n<ul>\n<li><strong>HFpEF accounts for ~50% of all heart failure cases</strong>, especially in older adults, hypertensives, and diabetics.</li>\n<li><strong>Conventional therapies</strong> used in <strong>HFrEF (e.g., ACEI, ARB, beta-blockers)</strong> have <strong>not consistently shown mortality benefit</strong> in HFpEF, though they may be used symptomatically or to treat comorbidities.</li>\n<li>The <strong>FDA-approved drugs for HFpEF</strong> are:\n<ul>\n<li><strong>SGLT2 inhibitors</strong> (e.g., <strong>empagliflozin</strong>, dapagliflozin): These have demonstrated <strong>reduction in HF hospitalizations</strong> and <strong>improvement in quality of life</strong>, even in <strong>non-diabetic patients</strong> with HFpEF.</li>\n<li><strong>ARNI (Sacubitril-Valsartan)</strong>: Shown to improve outcomes in some subsets of HFpEF.</li>\n</ul>\n</li>\n</ul>\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Digoxin (Option A): </strong>Digoxin is generally not indicated in HFpEF unless there's concomitant atrial fibrillation requiring rate control. It has no proven mortality benefit in HFpEF.</p>\n<p><strong>Furosemide (Option B):</strong> Diuretics provide <strong>symptomatic relief</strong> of congestion, but do <strong>not modify disease progression or mortality</strong> in HFpEF.</p>\n<p><strong>Angiotensin receptor blocker (Option C): </strong>ARBs (like candesartan) may be used in <strong>selected patients</strong> with hypertension or other comorbidities, but have no mortality benefit in HFpEF.</p>",
      "correct_choice_id": 54,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 7,
      "choices": [
        {
          "id": 61,
          "text": "<p><span style=\"font-size:12.0pt;\">Drug interaction with furosemide</span></p>"
        },
        {
          "id": 62,
          "text": "<p><span style=\"font-size:12.0pt;\">Drug interaction with ramipril</span></p>"
        },
        {
          "id": 63,
          "text": "<p><span style=\"font-size:12.0pt;\">Fluid retention due to rofecoxib</span></p>"
        },
        {
          "id": 64,
          "text": "<p><span style=\"font-size:12.0pt;\">Impairment of renal function</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">An elderly woman with a history of heart failure is being managed with furosemide and ramipril. She recently visited her family physician for left knee pain and was prescribed rofecoxib. Two weeks later, she presents to the emergency department with breathlessness and pedal edema. What is the most likely cause of her current symptoms?</span></p>",
      "unique_key": "DT1192993",
      "question_audio": null,
      "question_video": null,
      "map_id": 1192993,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p>Rofecoxib is a <strong>selective COX-2 inhibitor</strong> NSAID that was previously used for pain relief due to its reduced gastrointestinal side effects. However, like all NSAIDs, it can cause <strong>sodium and water retention</strong>, which may <strong>worsen heart failure</strong>, especially in the elderly or in patients on ACE inhibitors or diuretics.</p>\n<ul>\n<li>In this patient with <strong>pre-existing heart failure</strong>, the addition of rofecoxib likely led to <strong>fluid retention</strong>, manifesting as <strong>breathlessness</strong> and <strong>pedal edema</strong>.</li>\n<li>The mechanism involves <strong>inhibition of renal prostaglandin synthesis</strong>, leading to decreased renal perfusion, salt retention, and fluid overload.</li>\n<li>Though NSAIDs may <strong>potentiate nephrotoxicity</strong> when combined with <strong>ACE inhibitors and diuretics</strong>, the <strong>dominant clinical presentation here (pulmonary edema + peripheral edema)</strong> points to <strong>fluid overload</strong>, not isolated renal failure.</li>\n</ul>\n<p>Rofecoxib and other COX-2 inhibitors are therefore <strong>contraindicated in patients with severe or unstable heart failure</strong> due to this risk.</p>\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Drug interaction with furosemide (Option A): </strong>Rofecoxib does not directly interact with furosemide, though it may blunt its natriuretic effect indirectly via prostaglandin inhibition. However, this is not the primary mechanism of decompensation here.</p>\n<p><strong>Drug interaction with ramipril (Option B): </strong>Rofecoxib and ramipril together can increase the risk of renal dysfunction, but fluid retention and heart failure exacerbation is the more immediate and likely clinical cause in this scenario.</p>\n<p><strong>Impairment of renal function (Option D): </strong>While NSAIDs can cause renal impairment, the acute symptoms of pulmonary edema and fluid overload are better explained by volume retention, not isolated renal dysfunction.</p>",
      "correct_choice_id": 63,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 8,
      "choices": [
        {
          "id": 71,
          "text": "<p><span style=\"font-size:12.0pt;\">Loop diuretic administration would result in a decrease in mortality</span></p>"
        },
        {
          "id": 72,
          "text": "<p><span style=\"font-size:12.0pt;\">Digoxin is more effective than ACE inhibitors in providing symptomatic relief</span></p>"
        },
        {
          "id": 73,
          "text": "<p><span style=\"font-size:12.0pt;\">Administration of a &beta;-blocker improve symptoms and exercise tolerance</span></p>"
        },
        {
          "id": 74,
          "text": "<p><span style=\"font-size:12.0pt;\">Administration of spironolactone has no effect on the incidence of sudden cardiac death</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 68-year-old man is admitted with chronic congestive heart failure. Which of the following statements is true regarding the management principles in this patient?</span></p>",
      "unique_key": "DT1192996",
      "question_audio": null,
      "question_video": null,
      "map_id": 1192996,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p><strong>&beta;-blockers (metoprolol, bisoprolol, carvedilol)</strong> are cornerstone agents in the management of <strong>chronic stable heart failure with reduced ejection fraction (HFrEF)</strong>. Large randomized trials such as MERIT-HF (metoprolol) and CIBIS-II (bisoprolol) have demonstrated that these agents:</p>\n<ul>\n<li><strong>Improve left ventricular ejection fraction (LVEF)</strong></li>\n<li>Enhance <strong>symptom control and functional class</strong></li>\n<li>Increase <strong>exercise tolerance</strong></li>\n<li><strong>Reduce all-cause and cardiovascular mortality</strong></li>\n</ul>\n<p>They are typically started at <strong>low doses</strong> and up-titrated cautiously once patients are <strong>euvolemic</strong>, as they may initially worsen symptoms if introduced during acute decompensation.</p>\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Loop diuretic administration would result in a decrease in mortality (Option A): </strong>Loop diuretics (e.g., furosemide) are very effective in relieving symptoms like edema and dyspnea, but <strong>they do not reduce mortality</strong>. They are used for <strong>symptomatic relief</strong>, not for disease modification.</p>\n<p><strong>Digoxin is more effective than ACE inhibitors in providing symptomatic relief (Option B): ACE inhibitors</strong> not only provide <strong>symptomatic benefit</strong> but also <strong>reduce mortality</strong> and prevent remodeling. <strong>Digoxin</strong> mainly provides symptomatic improvement and reduces hospitalization, but does <strong>not improve survival</strong>.</p>\n<p><strong>Administration of spironolactone has no effect on the incidence of sudden cardiac death (Option D): </strong>The RALES trial showed that low-dose spironolactone in patients with severe heart failure led to a <strong>significant reduction in sudden cardiac death and overall mortality</strong> by antagonizing aldosterone's harmful effects on the myocardium.</p>",
      "correct_choice_id": 73,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 9,
      "choices": [
        {
          "id": 81,
          "text": "<p><span style=\"font-size:12.0pt;\">Bioavailablity</span></p>"
        },
        {
          "id": 82,
          "text": "<p><span style=\"font-size:12.0pt;\">Half life</span></p>"
        },
        {
          "id": 83,
          "text": "<p><span style=\"font-size:12.0pt;\">Plasma protein binding</span></p>"
        },
        {
          "id": 84,
          "text": "<p><span style=\"font-size:12.0pt;\">Renal clearance</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 65-year-old man was advised to start oral digoxin at a dose of 250 &mu;g daily. His doctor explained that the full effect of this treatment would not be apparent for at least a week. Which one of the following pharmacokinetic variables did the doctor use to give this explanation?</span></p>",
      "unique_key": "DT1192998",
      "question_audio": null,
      "question_video": null,
      "map_id": 1192998,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p>The clinical explanation provided by the doctor refers to the time taken to reach <strong>steady-state concentration</strong>, which is directly related to the <strong>half-life</strong> of a drug.</p>\r\n<ul>\r\n<li><strong>Digoxin</strong> has a <strong>half-life of approximately 36-48 hours</strong> in patients with normal renal function. This means that with regular dosing, the drug concentration <strong>gradually accumulates</strong>, and it typically takes about <strong>4-5 half-lives</strong> to reach a steady state where the full therapeutic effect is seen.</li>\r\n<li>Therefore, it will take about <strong>7-10 days</strong> for digoxin to reach steady-state levels, consistent with the doctor's statement that the full effect may take a week.</li>\r\n<li>Although <strong>bioavailability</strong> (&sim;70%) affects the <strong>extent</strong> of drug absorption, it does not determine the <strong>rate</strong> at which steady state is reached. Likewise, <strong>plasma protein binding</strong> and <strong>renal clearance</strong> influence drug distribution and elimination but are not used alone to estimate time to steady state; <strong>half-life</strong> is the key pharmacokinetic determinant for that. <strong>(Options A, C &amp; D ruled out)</strong></li>\r\n</ul>",
      "correct_choice_id": 82,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 10,
      "choices": [
        {
          "id": 91,
          "text": "<p><span style=\"font-size:12.0pt;\">Blood transfusion</span></p>"
        },
        {
          "id": 92,
          "text": "<p><span style=\"font-size:12.0pt;\">Intravenous iron infusion</span></p>"
        },
        {
          "id": 93,
          "text": "<p><span style=\"font-size:12.0pt;\">Start intramuscular vitamin B12 and oral folic acid</span></p>"
        },
        {
          "id": 94,
          "text": "<p><span style=\"font-size:12.0pt;\">Thrombolysis with t-PA</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 68-year-old woman is admitted with severe acute dyspnea. She reports progressive breathlessness over the past three months. On examination, she is tachycardic (HR 120 bpm), hypotensive (BP 95/55 mmHg), and has elevated JVP and bilateral inspiratory crackles. Fundoscopy reveals hemorrhages in both eyes.<br>Investigations show:<br>Hemoglobin: 5.6 g/dL<br>MCV: 118 fL<br>White cell count: 3.4 &times; 109/L<br>Platelets: 95 &times; 109/L<br>She is given 80 mg IV furosemide, which results in excellent diuresis. What is the next most appropriate immediate step in her management?</span></p>",
      "unique_key": "DT1193003",
      "question_audio": null,
      "question_video": null,
      "map_id": 1193003,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p>This patient presents with <strong>severe symptomatic anemia (Hb 5.6 g/dL)</strong> with <strong>macrocytosis (MCV 118 fL)</strong>, <strong>pancytopenia</strong>, and <strong>hemodynamic instability (hypotension, tachycardia, dyspnea, pulmonary congestion)</strong>, a clinical picture consistent with <strong>megaloblastic anemia causing high-output cardiac failure</strong>.</p>\r\n<ul>\r\n<li>The immediate clinical priority is to address the <strong>critical anemia</strong> and prevent <strong>cardiovascular collapse</strong>.</li>\r\n<li><strong>Blood transfusion is the most appropriate immediate step</strong>, especially since the patient is acutely decompensated, showing signs of heart failure. It should be done <strong>cautiously with diuretic cover</strong> (already administered here), to avoid volume overload.</li>\r\n<li>Although long-term management involves <strong>vitamin B12 and folate replacement</strong>, initiating this alone will not resolve the current life-threatening anemia. <strong>(Option C ruled out)</strong></li>\r\n<li>It is also important to avoid folate monotherapy in B12 deficiency as it may worsen <strong>neurological complications</strong> (e.g., subacute combined degeneration of spinal cord).</li>\r\n<li><strong>Explanation of Other Options:</strong></li>\r\n</ul>\r\n<p><strong>Intravenous iron infusion (Option B):</strong> Iron deficiency is not the most likely cause here, given the <strong>macrocytosis</strong> and <strong>pancytopenia</strong>. Iron is contraindicated unless proven iron deficiency, and certainly not urgent in this hemodynamic setting.</p>\r\n<p><strong>Thrombolysis with t-PA (Option D):</strong> There is no evidence of <strong>thromboembolic disease</strong> such as pulmonary embolism. Her symptoms are due to severe anemia-induced heart failure, not a thrombotic event.</p>",
      "correct_choice_id": 91,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 11,
      "choices": [
        {
          "id": 101,
          "text": "<p><span style=\"font-size:12.0pt;\">Propranolol</span></p>"
        },
        {
          "id": 102,
          "text": "<p><span style=\"font-size:12.0pt;\">Atenolol</span></p>"
        },
        {
          "id": 103,
          "text": "<p><span style=\"font-size:12.0pt;\">Carvedilol</span></p>"
        },
        {
          "id": 104,
          "text": "<p><span style=\"font-size:12.0pt;\">Labetolol</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following is a cardioselective beta blocker?</span></p>",
      "unique_key": "DT1193004",
      "question_audio": null,
      "question_video": null,
      "map_id": 1193004,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p><strong>Cardioselective beta blockers</strong>, also known as <strong>&beta;1-selective blockers</strong>, primarily block &beta;1 receptors in the heart, with minimal effect on &beta;2 receptors found in bronchi and vasculature. This selectivity makes them preferable in patients with comorbid <strong>bronchial asthma or COPD</strong>, where &beta;2 blockade may cause bronchospasm.</p>\n<p><strong>Atenolol</strong> is a prototypical <strong>&beta;1-selective (cardioselective)</strong> beta blocker. Other cardioselective agents include:</p>\n<ul>\n<li>Metoprolol</li>\n<li>Bisoprolol</li>\n<li>Esmolol (shortest acting; used for intraoperative arrhythmias)</li>\n<li>Acebutolol</li>\n<li>Nebivolol</li>\n<li>Celiprolol (has partial &beta;2 agonist activity in addition to &beta;1 selectivity)</li>\n</ul>\n<p>These drugs reduce heart rate, cardiac output, and myocardial oxygen demand with <strong>less bronchoconstriction risk</strong> compared to non-selective agents.</p>\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Propranolol (Option A): </strong>Propranolol is a <strong>non-selective beta blocker</strong>, affecting both &beta;1 and &beta;2 receptors. Its &beta;2 antagonism can precipitate bronchospasm, making it unsuitable for asthmatics.</p>\n<p><strong>Carvedilol (Option C): </strong>Carvedilol is a <strong>non-selective beta blocker with additional alpha-1 blocking</strong> activity, leading to vasodilation. It is useful in heart failure but <strong>not cardioselective</strong>.</p>\n<p><strong>Labetalol (Option D): </strong>Labetalol blocks both <strong>beta (non-selective)</strong> and <strong>alpha-1</strong> receptors. It is primarily used in hypertensive emergencies and during pregnancy-induced hypertension (PIH), not considered cardioselective.</p>\n<p><strong>Key Takeaway:</strong></p>\n<br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20250922abe67407-c74f-490c-a1f6-ff7c7bd92939.png\">",
      "correct_choice_id": 102,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 12,
      "choices": [
        {
          "id": 111,
          "text": "<p><span style=\"font-size:12.0pt;\">Cor pulmonale</span></p>"
        },
        {
          "id": 112,
          "text": "<p><span style=\"font-size:12.0pt;\">Left atrial myxoma</span></p>"
        },
        {
          "id": 113,
          "text": "<p><span style=\"font-size:12.0pt;\">Left ventricular hypertrophy</span></p>"
        },
        {
          "id": 114,
          "text": "<p><span style=\"font-size:12.0pt;\">Occlusive coronary atherosclerosis</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 61-year-old man is found to have a sitting BP of 183/100 mmHg and a standing BP of 190/105 mmHg during a clinic visit. His heart rate is 81/min with an  irregularly irregular rhythm. On examination, there are no cardiac murmurs, but bibasilar crackles are present on chest auscultation. Which of the following pathological findings is most likely to be present?</span></p>",
      "unique_key": "DT1193011",
      "question_audio": null,
      "question_video": null,
      "map_id": 1193011,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p>This patient presents with features of uncontrolled hypertension, atrial fibrillation (irregularly irregular pulse), and bibasilar crackles indicating pulmonary congestion. The most likely underlying pathology is <strong>left ventricular hypertrophy (LVH)</strong>, which occurs as an <strong>adaptive response to chronic pressure overload</strong> from long-standing systemic hypertension.</p>\n<ul>\n<li><strong>LVH</strong> is the hallmark structural change in <strong>hypertensive cardiomyopathy</strong>, resulting from increased afterload.</li>\n<li>Over time, LVH leads to <strong>diastolic dysfunction</strong>, which impairs ventricular filling and raises left atrial pressure, resulting in pulmonary congestion (as evidenced by <strong>bibasilar crackles</strong>).</li>\n<li>The development of <strong>atrial fibrillation</strong> in this context reflects elevated left atrial pressure and volume due to impaired diastolic filling.</li>\n<li>There is no murmur, ruling out valvular causes, and the standing BP being higher than sitting suggests <strong>autonomic dysfunction is not a feature</strong>. Thus, <strong>left ventricular hypertrophy is the most likely pathological finding</strong> in this scenario.</li>\n</ul>\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Cor pulmonale (Option A): </strong>Cor pulmonale refers to right heart failure secondary to <strong>chronic lung disease or pulmonary hypertension</strong>, not systemic hypertension. Also, there is no mention of chronic lung disease or peripheral edema.</p>\n<p><strong>Left atrial myxoma (Option B):</strong> While atrial myxomas can present with constitutional symptoms, embolic phenomena, or obstructive signs mimicking mitral stenosis, they are rare and would typically produce a <strong>tumor plop or murmur</strong> on auscultation, which is <strong>absent</strong> here.</p>\n<p><strong>Occlusive coronary atherosclerosis (Option D): </strong>Although coronary artery disease is a common comorbidity in hypertensive patients, this clinical picture lacks features of <strong>angina</strong>, <strong>myocardial infarction</strong>, or <strong>ischemic ECG changes</strong>. The findings are better explained by hypertensive heart disease with diastolic dysfunction.</p>",
      "correct_choice_id": 113,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 13,
      "choices": [
        {
          "id": 121,
          "text": "<p><span style=\"font-size:12.0pt;\">No conclusion can be drawn from this result</span></p>"
        },
        {
          "id": 122,
          "text": "<p><span style=\"font-size:12.0pt;\">Pulmonary embolism is the most likely cause of her symptoms</span></p>"
        },
        {
          "id": 123,
          "text": "<p><span style=\"font-size:12.0pt;\">If a further BNP level is above 50 pg/ml after one hour then this is diagnostic of heart failure</span></p>"
        },
        {
          "id": 124,
          "text": "<p><span style=\"font-size:12.0pt;\">Heart failure is unlikely to be the cause of her dyspnoea</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 72-year-old woman is admitted with acute dyspnoea to the Emergency Department. Oxygen saturations are 94% on 30% supplementary oxygen, and her respiratory rate is 30/min. A rapid B-type natriuretic peptide (BNP) assay is reported as follows: BNP 62 pg/ml. What is the best interpretation of this result?</span></p>",
      "unique_key": "DT1193020",
      "question_audio": null,
      "question_video": null,
      "map_id": 1193020,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p><strong>B-type natriuretic peptide (BNP)</strong> is a hormone secreted predominantly by the <strong>left ventricular myocardium</strong> in response to <strong>volume expansion and increased wall stress</strong>, making it a key biomarker in the evaluation of suspected <strong>heart failure</strong>.</p>\n<ul>\n<li>In acute settings, <strong>BNP levels below 100 pg/mL</strong> have a <strong>high negative predictive value</strong> for ruling out heart failure.</li>\n<li>In this patient, a BNP of <strong>62 pg/mL</strong> falls well below the diagnostic threshold, <strong>making heart failure unlikely as the cause</strong> of her acute dyspnoea.</li>\n<li>BNP levels can be mildly elevated in other conditions like <strong>chronic kidney disease</strong>, <strong>pulmonary hypertension</strong>, and <strong>sepsis</strong>, but <strong>a low BNP effectively excludes significant heart failure</strong> as the etiology.</li>\n</ul>\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>No conclusion can be drawn from this result (Option A): </strong>A <strong>low BNP (&lt;100 pg/mL)</strong> is quite conclusive in <strong>ruling out heart failure</strong> in the acute setting, particularly if measured accurately and early in the presentation.</p>\n<p><strong>Pulmonary embolism is the most likely cause of her symptoms (Option B): </strong>While <strong>PE can cause dyspnoea</strong>, this <strong>cannot be concluded based solely on a BNP level</strong>. BNP is not specific for PE, and further clinical, imaging (e.g., CTPA), or D-dimer evidence would be required.</p>\n<p><strong>If a further BNP level is above 50 pg/ml after one hour then this is diagnostic of heart failure (Option C): </strong>There is <strong>no validated diagnostic protocol</strong> involving serial BNP levels within 1 hour. Additionally, a value of 50 pg/mL is below diagnostic thresholds used for heart failure.</p>",
      "correct_choice_id": 124,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 14,
      "choices": [
        {
          "id": 131,
          "text": "<p><span style=\"font-size:12.0pt;\">Pulsus biferiens</span></p>"
        },
        {
          "id": 132,
          "text": "<p><span style=\"font-size:12.0pt;\">Gallop rhythm</span></p>"
        },
        {
          "id": 133,
          "text": "<p><span style=\"font-size:12.0pt;\">Tachycardia</span></p>"
        },
        {
          "id": 134,
          "text": "<p><span style=\"font-size:12.0pt;\">Peripheral oedema</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 66-year-old man with a history of chronic obstructive pulmonary disease and ischaemic heart disease is taken to the Emergency Department with dyspnoea. On examination, his respiratory rate is 24/min, JVP is not elevated, and crackles are heard in both lung bases. Which other finding would most strongly indicate that his dyspnoea is secondary to isolated left ventricular failure?</span></p>",
      "unique_key": "DT1193026",
      "question_audio": null,
      "question_video": null,
      "map_id": 1193026,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p>In a patient presenting with <strong>dyspnoea and bilateral basal crackles</strong>, it is important to differentiate between pulmonary and cardiac causes of respiratory distress. Given the absence of elevated JVP and peripheral edema, <strong>isolated left ventricular failure (LVF)</strong> is a strong consideration.</p>\n<ul>\n<li>The presence of a <strong>gallop rhythm</strong>, specifically <strong>S3</strong>, is a highly suggestive and <strong>early auscultatory sign of left ventricular dysfunction</strong>. It reflects <strong>increased left ventricular filling pressures</strong> and is classically heard in <strong>congestive heart failure</strong>.</li>\n<li>The <strong>classic clinical triad</strong> in <strong>left ventricular failure</strong> includes:\n<ul>\n<li><strong>Pulsus alternans</strong></li>\n<li><strong>Gallop rhythm (S3)</strong></li>\n<li><strong>Bibasal crepitations</strong></li>\n</ul>\n</li>\n<li>These findings support elevated left-sided pressures causing pulmonary congestion, independent of right heart involvement (e.g., no JVP elevation or peripheral edema).</li>\n</ul>\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Pulsus biferiens (Option A): </strong>Pulsus biferiens is characterized by <strong>two systolic peaks</strong> and is typically seen in <strong>hypertrophic cardiomyopathy</strong> and <strong>combined aortic stenosis with aortic regurgitation</strong>, not in isolated LVF.</p>\n<p><strong>Tachycardia (Option C): </strong>While <strong>tachycardia</strong> may be present in LVF due to sympathetic stimulation, it is a <strong>nonspecific</strong> finding and not diagnostic for left-sided failure.</p>\n<p><strong>Peripheral oedema (Option D): Peripheral edema</strong> indicates <strong>right-sided or biventricular failure</strong>, and its absence here supports isolated left-sided involvement.</p>",
      "correct_choice_id": 132,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 15,
      "choices": [
        {
          "id": 141,
          "text": "<p><span style=\"font-size:12.0pt;\">Bisferiens pulse</span></p>"
        },
        {
          "id": 142,
          "text": "<p><span style=\"font-size:12.0pt;\">Wide pulse pressure</span></p>"
        },
        {
          "id": 143,
          "text": "<p><span style=\"font-size:12.0pt;\">Warm peripheries</span></p>"
        },
        {
          "id": 144,
          "text": "<p><span style=\"font-size:12.0pt;\">Pulsus alternans</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 74-year-old man with a history of ischaemic heart disease and left ventricular dysfunction presents with dyspnoea. He reports not taking his diuretics for the past three days. On examination, there are bilateral mid-zone crackles and a respiratory rate of 30/min. Which of the following clinical findings is most specific to his current presentation?</span></p>",
      "unique_key": "DT1193030",
      "question_audio": null,
      "question_video": null,
      "map_id": 1193030,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p>This patient presents with <strong>acute decompensated left ventricular failure</strong>, likely precipitated by missed diuretics. A <strong>specific and distinguishing clinical finding</strong> in this context is <strong>pulsus alternans</strong>, a physical sign characterized by <strong>alternating strong and weak peripheral pulses</strong>, despite a regular rhythm.</p>\n<ul>\n<li><strong>Pathophysiology:</strong> Pulsus alternans occurs due to <strong>severely impaired left ventricular contractility</strong>, leading to variations in stroke volume from beat to beat.</li>\n<li><strong>Detection:</strong> It can be palpated at the radial or femoral artery or seen as alternating systolic pressures when using a sphygmomanometer.</li>\n<li>It signifies <strong>advanced left ventricular systolic dysfunction</strong> and is associated with <strong>poor prognosis</strong>.</li>\n</ul>\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Bisferiens pulse (Option A): </strong>This is a <strong>double-peaked pulse</strong> and is associated with <strong>mixed aortic valve disease</strong> (i.e., both stenosis and regurgitation) or <strong>hypertrophic cardiomyopathy</strong>, not typical in isolated LV failure.</p>\n<p><strong>Wide pulse pressure (Option B): </strong>Seen in <strong>aortic regurgitation</strong> and <strong>hyperkinetic states</strong> (e.g., thyrotoxicosis, pregnancy, fever), not specifically in LV failure.</p>\n<p><strong>Warm peripheries (Option C): </strong>In <strong>left-sided heart failure</strong>, especially with low output, peripheries are usually <strong>cool</strong> due to reduced perfusion. Warm peripheries are typical of <strong>high-output heart failure</strong> or <strong>compensated states</strong>.</p>\n<p><strong>Key Takeaway:</strong></p>\n<p><strong>Pulse Types and Their Clinical Associations</strong></p>\n<br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20250922cb850aad-829e-48b2-86b8-e39b53df83ff.png\">",
      "correct_choice_id": 144,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 16,
      "choices": [
        {
          "id": 151,
          "text": "<p><span style=\"font-size:12.0pt;\">Cardiac computed tomography</span></p>"
        },
        {
          "id": 152,
          "text": "<p><span style=\"font-size:12.0pt;\">Echocardiography</span></p>"
        },
        {
          "id": 153,
          "text": "<p><span style=\"font-size:12.0pt;\">Exercise ECG</span></p>"
        },
        {
          "id": 154,
          "text": "<p><span style=\"font-size:12.0pt;\">MUGA scan</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 66-year-old man with ischaemic heart disease is about to start a chemotherapy regimen that includes doxorubicin. Since doxorubicin is known to cause cardiotoxicity, you want to accurately assess his left ventricular function prior to treatment. Which one of the following is the most accurate method to determine his left ventricular function?</span></p>",
      "unique_key": "DT1193033",
      "question_audio": null,
      "question_video": null,
      "map_id": 1193033,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p>Doxorubicin, an anthracycline chemotherapy drug, is well known for its <strong>dose-dependent cardiotoxicity</strong> which can lead to <strong>dilated cardiomyopathy and heart failure</strong>. Therefore, <strong>accurate baseline and follow-up assessments of </strong>left ventricular ejection fraction<strong> (LVEF)</strong> are essential before and during therapy.</p>\n<p>The <strong>Multi-Gated Acquisition (MUGA) scan</strong> is a <strong>nuclear imaging technique</strong> that uses technetium-99m and a gamma camera to accurately quantify LVEF.</p>\n<ul>\n<li>It is <strong>highly reproducible and more accurate than echocardiography</strong> for serial measurements of LVEF, which makes it particularly useful in monitoring patients receiving cardiotoxic chemotherapy (e.g., doxorubicin).</li>\n<li>MUGA scans are considered the <strong>preferred imaging modality</strong> for LVEF monitoring when precise quantification is required.</li>\n</ul>\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Cardiac computed tomography (Option A): </strong>Cardiac CT is mainly used for <strong>coronary artery assessment</strong> (e.g., calcium scoring, coronary CT angiography). It is <strong>not ideal</strong> for accurate LVEF quantification compared to MUGA or MRI.</p>\n<p><strong>Echocardiography (Option B): </strong>Though commonly used, echocardiography is <strong>operator-dependent</strong> and less reproducible than MUGA when <strong>accurate and serial measurements</strong> of LVEF are needed. It remains a <strong>useful first-line</strong> tool but is not the most accurate compared to MUGA.</p>\n<p><strong>Exercise ECG (Option C):</strong> It is used to evaluate <strong>ischemia and exercise capacity</strong>, not ventricular function or LVEF. It offers <strong>no direct structural or functional data</strong> on LV performance.</p>",
      "correct_choice_id": 154,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    }
  ]
}